Under Nasdaq Marketplace Rule 5810(c)(3)(A) and as noted in both the related deficiency letter
and the transfer approval letter, the Company will have 180 calendar days, or until March 15, 2010, to regain compliance with the $1.
5 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT) -- World Heart Corporation ("WorldHeart" or "Company"), a developer of mechanical circulatory systems, announced today that on February 1, 2010, the Company received a NASDAQ Staff Deficiency Letter
indicating that the Company does not comply with NASDAQ Listing Rule 5605.
Nasdaq: DSTI), a developer of solar photovoltaic products based on CIGS thin-film deposition technology announced today that on December 30, 2009 it received a NASDAQ Staff Deficiency Letter
from The NASDAQ Stock Market indicating that the Company temporarily did not comply with the audit committee requirement for continued listing on NASDAQ as set forth in Marketplace Rule 5605(c)(2).
The Nasdaq Staff Deficiency Letter
with respect to the MVPHS Rule indicated that the Company is not in compliance with Listing Rule 5550(a)(5) because for the last 30 consecutive trading days, the Company's common stock has not maintained a minimum market value of publicly held shares of $1,000,000, as required for continued listing.
If the examination revealed the adviser failed to comply with the act or, for example, that its internal controls were deficient, the SEC will send the adviser a deficiency letter
outlining the violations and requesting corrective action.
The FDA issues a major deficiency letter
to the applicant when the PMA lacks significant information necessary for FDA to complete its review or to determine whether there is reasonable assurance that the device is safe and effective for its intended use.
24, 2013 /PRNewswire/ -- The InterGroup Corporation (NASDAQ: INTG) today announced that, on September 20, 2013, it received a Staff Deficiency Letter
from the Nasdaq Stock Market Listing Qualifications Department indicating that the Company no longer complies with Nasdaq's audit committee listing requirements as set forth in Listing Rule 5605 due to the resignation of Josef A.
On July 19, 2010, Tongxin received a NASDAQ Staff Deficiency Letter
stating that the company was no longer in compliance with NASDAQ Listing Rules due to its failure to file a Form 20-F for the period ended December 31, 2009.
Separately, on October 11, 2010, the Company received a Nasdaq Staff Deficiency Letter
indicating that the Company no longer complies with the Market Value of Publicly Held Shares requirement for continued listing set forth in NASDAQ Listing Rule 5450(b)(2)(C).
It is Nasdaq's customary practice to issue a deficiency letter
when a listed company does not meet the standards of the Listing Rules.
The Company received a second Deficiency Letter
from the Staff dated October 20, 2009, relating to the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarter ended August 31, 2009.
NASDAQ: EONC) said that on August 15, 2012 it received a NASDAQ deficiency letter
from the NASDAQ Stock Market stating that for the last 30 consecutive business days, the closing bid price per share of the company's common stock has been below the $1 minimum share requirement.